Peritoneal Carcinomatosis
Conditions
Brief summary
Evaluation of clinical outcome and economical aspects in the treatment of patients with peritoneal carcinomatosis.
Detailed description
Peritoneal carcinomatosis is a dooming finding with no hope for cure and a steadily decrease in quality of life. Cytoreductive surgery with intraperitoneal chemotherapy (CRS HIPEC) offers a small but proven chance for cure. The implementation of a CRS HIPEC and PIPAC programme in a Swiss tertiary care hospital is evaluated. When a patient is deemed non resectable, pressurized intraperitoneal aerosol chemotherapy (PIPAC) administered laparoscopically may confer effective palliation.
Interventions
None listed
Sponsors
Kantonsspital Winterthur KSW
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and Women \>18 years * Tumour board decision for CRS and intraoperative chemotherapy
Exclusion criteria
* Missing Tumour board decision for CRS and intraoperative chemotherapy * Pregnancy * Age \<18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative surgical complications | 90 days | Reporting and grading of postoperative surgical complications (according to Dindo) |
| Rehospitalisation | 90 days | Rehospitalisation: (yes/no), time frame, cause of rehospitalisation |
| Disease-free survival | 5 years | Time to recurrence measured since diagnosis/Intervention (in months) |
| Overall Survival | 5 years | All cause mortality since diagnosis/Intervention (in months) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of quality of life | 5 years | Validated measurements of health-related quality of life according to the EORTC manual in terms of general quality of life: EORTC-QLQ30; disease-specific quality of life: EORTC-CR29 (colorectal cancers), and health-utility (EQ-5D). |
| Cost-effectiveness | 90 days | Aggregation of costs, charges, and revenues for the whole series and comparison with alternative treatment option as clinically relevant, chemotherapy alone and palliative surgery alone. |
| Cost | 90 days | At the level of individual patient Cost in terms of hospital charges and expenses in Swiss Francs |
| Revenues | 90 days | At the level of individual patient Revenues in Swiss Francs as billed according to the DRG and case-mix index |
| Cost-utility analysis | 90 days | Calculation and comparison of QUALY (quality-adjusted life years derived from EQ-5D) for competing treatment strategies taking advantage of published figures and own data, e.g. cost of a systemic palliative chemotherapy compared to cost of an intraperitoneal chemotherapy |
Countries
Switzerland
Contacts
Primary ContactMichel Adamina, Prof/MD/MSc
Backup ContactKantonsspital Winterthur
Outcome results
None listed